Latest profit margin for Insight Molecular Diagnostics: -2137.33% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
The latest profit margin for IMDX is -2137.33% as of September 2026. That compares with -1380.69% in the prior-year period — down 54.8% year over year. That is below the Technology sector average of 22.47%. Investors often review this figure alongside Insight Molecular Diagnostics's historical trend and sector peers before judging valuation or financial health.
Over the past year, IMDX's profit margin moved from -1380.69% to -2137.33% — a 54.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Insight Molecular Diagnostics's valuation or profitability profile.
Against Technology companies, IMDX currently prints -2137.33% for profit margin, while the sector average sits near 22.47%. That is roughly 9611.6% below the sector mean. Large gaps often invite a closer look at Insight Molecular Diagnostics's growth, margins, and balance sheet.
Profit Margin shows how effectively Insight Molecular Diagnostics converts resources into returns. At -2137.33%, IMDX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1380.69% in the prior-year period — down 54.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting IMDX's profit margin (-2137.33%), review year-over-year change from -1380.69%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.